March 20, 2018 / 6:03 PM / a month ago

BRIEF-Biophytis Files For Orphan Drug Designation For Sarconeos In Duchenne Muscular Dystrophy‍​

March 20 (Reuters) - BIOPHYTIS SA:

* FILES FOR ORPHAN DRUG DESIGNATION FOR SARCONEOS IN DUCHENNE MUSCULAR DYSTROPHY (DMD)‍​

* FILED FOR ORPHAN DRUG DESIGNATION WITH THE EUROPEAN MEDICINES AGENCY (EMA)‍​

* A PHARMACOKINETIC PHASE I/II MYODA-PK STUDY TO BE INITIATED IN 2018‍​

* A PHASE II/III EFFICACY STUDY, MYODA-INTEREST, THAT COULD START IN 2019 Source text: bit.ly/2pvTB2z Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below